Dr. Mark Kirchhof, MD, PhD, FRCPC, Head of the Division of Dermatology, Faculty of Medicine, University of Ottawa and The Ottawa Hospital, provides an overview of the current state of knowledge about psoriasis and COVID-19. Research is constantly evolving and the information presented in this webinar reflects the date of its original publication (May 2, 2022).

Have you taken guselkumab (Tremfya)? We need your valuable input! This anonymous survey will gather patient perspectives to inform treatment recommendations to the Common Drug Review (CDR).  Your valuable patient feedback can help to inform drug review and decision-making on public drug reimbursements.

Significant numbers of people in Canada with psoriasis and psoriatic arthritis (psoriatic disease) say their condition has a significant impact on work and that they need information and support on a variety of workplace-related topics to help them navigate their accommodation needs.